Literature DB >> 9552416

Aberrations of the G1- and G1/S-regulating genes in human cancer.

J Bartkova1, J Lukas, J Bartek.   

Abstract

Deregulated cell proliferation is the hallmark of cancer, and convergent data from the fields of cell-cycle research and molecular oncology have revealed the key role played by abnormalities of the cell-cycle control genes in multistep tumorigenesis. Along with the p53-mediated DNA damage checkpoint, the G1-governing pathway of D-type cyclins, their partner cyclin-dependent kinases (Cdk), Cdk inhibitors, and the retinoblastoma protein constitute a functional unit and prominent oncogenic target. We have learned a great deal about the molecular basis of G1 phase progression and G1/S transition, their proto-oncogenic defects, and potential clinical significance including diagnostic and prognostic applications and new approaches to gene therapy of cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9552416     DOI: 10.1007/978-1-4615-5371-7_16

Source DB:  PubMed          Journal:  Prog Cell Cycle Res        ISSN: 1087-2957


  19 in total

1.  Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.

Authors:  Agnieszka K Witkiewicz; Dayana B Rivadeneira; Adam Ertel; Jessica Kline; Terry Hyslop; Gordon F Schwartz; Paolo Fortina; Erik S Knudsen
Journal:  Am J Pathol       Date:  2011-07-12       Impact factor: 4.307

2.  Cyclin D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx.

Authors:  Malgorzata Rydzanicz; Pawel Golusinski; Daniela Mielcarek-Kuchta; Wojciech Golusinski; Krzysztof Szyfter
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-10-29       Impact factor: 2.503

3.  Mutant alleles of Schizosaccharomyces pombe rad9(+) alter hydroxyurea resistance, radioresistance and checkpoint control.

Authors:  H Hang; S J Rauth; K M Hopkins; H B Lieberman
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

4.  Distinct action of the retinoblastoma pathway on the DNA replication machinery defines specific roles for cyclin-dependent kinase complexes in prereplication complex assembly and S-phase progression.

Authors:  Wesley A Braden; Jon M Lenihan; Zhengdao Lan; K Scott Luce; William Zagorski; Emily Bosco; Michael F Reed; Jeanette G Cook; Erik S Knudsen
Journal:  Mol Cell Biol       Date:  2006-08-14       Impact factor: 4.272

5.  BRG-1 is required for RB-mediated cell cycle arrest.

Authors:  M W Strobeck; K E Knudsen; A F Fribourg; M F DeCristofaro; B E Weissman; A N Imbalzano; E S Knudsen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

6.  Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition.

Authors:  Hasan Siddiqui; David A Solomon; Ranjaka W Gunawardena; Ying Wang; Erik S Knudsen
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

7.  Modifications in cell cycle kinetics and in expression of G1 phase-regulating proteins in human amniotic cells after exposure to electromagnetic fields and ionizing radiation.

Authors:  S Lange; T Viergutz; M Simkó
Journal:  Cell Prolif       Date:  2004-10       Impact factor: 6.831

8.  Deletion of mouse rad9 causes abnormal cellular responses to DNA damage, genomic instability, and embryonic lethality.

Authors:  Kevin M Hopkins; Wojtek Auerbach; Xiang Yuan Wang; M Prakash Hande; Haiying Hang; Debra J Wolgemuth; Alexandra L Joyner; Howard B Lieberman
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

9.  RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult.

Authors:  Emily E Bosco; Christopher N Mayhew; Robert F Hennigan; Julien Sage; Tyler Jacks; Erik S Knudsen
Journal:  Nucleic Acids Res       Date:  2004-01-02       Impact factor: 16.971

10.  RB activity alters checkpoint response and chemosensitivity in lung cancer lines.

Authors:  Michael F Reed; William A Zagorski; Erik S Knudsen
Journal:  J Surg Res       Date:  2007-07-19       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.